Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31499406 | 1.00 | CALM1 (0.57) | CALM1TAAR1IDO1AGXTMAOB | |
| SCHEMBL9200966 | 0.93 | TAAR1 (0.60) | TAAR1IDO1AGXTMAOBHCAR2 | |
| SCHEMBL9351968 | 0.88 | TAAR1 (0.52) | CALM1TAAR1IDO1AGXTMAOB | |
| SCHEMBL6481288 | 0.83 | CALM1 (0.60) | CALM1TAAR1IDO1AGXTMAOB | |
| SCHEMBL754462 | 0.83 | MAOB (0.54) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL3890987 | 0.83 | TAAR1 (0.47) | TAAR1IDO1AGXTMAOBHCAR2 | |
| SCHEMBL1501356 | 0.83 | CYP11B1 (0.49) | TAAR1IDO1AGXTMAOBHCAR2 | |
| SCHEMBL1631126 | 0.83 | MAOB (0.54) | TAAR1IDO1AGXTMAOBSMN1; SMN2 | |
| SCHEMBL1539285 | 0.83 | TAAR1 (0.52) | TAAR1IDO1AGXTMAOBTDP1 | |
| SCHEMBL10877707 | 0.82 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120024884-A | Method for preparing high-performance hard carbon by using small organic molecules | 厦门稀土材料研究所 | 2025-05-23 | — | — | CN | claimed |
| CN-120024884-A | Method for preparing high-performance hard carbon by using small organic molecules | 厦门稀土材料研究所 | 2025-05-23 | — | — | CN | disclosed |
| EP-3661923-B1 | N-HETEROCYCLIC COMPOUNDS AS OREXIN 2 AGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-05-15 | — | — | EP | disclosed |
| CN-116535329-A | Synthetic method of NOBIN-type axial chiral biaryl compound and compound thereof | 湖南师范大学 | 2023-08-04 | — | — | CN | disclosed |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-02 | — | — | US | disclosed |
| CN-114230581-B | Multidentate organic ligand, preparation method and application thereof, metal supramolecular polymer and preparation method thereof | 吉林大学 | 2023-01-31 | — | — | CN | disclosed |
| CN-108069957-B | Prolyl hydroxylase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11440883-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-13 | — | — | US | disclosed |
| CN-111051295-B | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114230581-A | Multidentate organic ligand, preparation method and application thereof, metal supramolecular polymer and preparation method thereof | 吉林大学 | 2022-03-25 | — | — | CN | disclosed |
| EP-0529444-B1 | 2-Arylpropenic acids and their utilisation in the preparation of 5-ketoprofen | BAYER AG (DE) | 1997-04-16 | — | — | EP | disclosed |
| EP-0755923-A1 | AMELIORANT OR REMEDY FOR SYMPTOMS CAUSED BY ISCHEMIC DISEASES AND COMPOUNDS USEFUL THEREFOR | SUNTORY LIMITED (JP) | 1997-01-29 | — | — | EP | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5362907-A | Intermediates and their use in the preparation of s-ketoprofen | BAYER AKTIENGESELLSCHAFT (DE) | 1994-11-08 | — | — | US | disclosed |
| EP-0529444-A2 | 2-Arylpropenic acids and their utilisation in the preparation of 5-ketoprofen | BAYER AG (DE) | 1993-03-03 | — | — | EP | disclosed |
| CN-1015545-B | preparation method of glycolic acid derivative for treating diabetic complications | PFIZER (US) | 1992-02-19 | — | — | CN | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1007248-B | PROCESS FOR MANUFACTURING OF FLOOD SUGAR REDUCING MEDICINE-THIAZOLIDINEDIONS | PFIZER (US) | 1990-03-21 | — | — | CN | disclosed |
| CN-87100191-A | The hydroxy acid derivative of treatment diabetic complication | — | 1987-09-09 | — | — | CN | disclosed |
| CN-86104075-A | Preparation method of hypoglycemic agent-thiazolidinedione | — | 1987-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440883-B2 | Heterocyclic compound and use thereof | HCRTR2, HCRTR1, CNR2 | CALM1 1612/4885TAAR1 37/4885IDO1 789/4885 |
| US-20230063805-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CNR2 | CALM1 1612/4885TAAR1 37/4885IDO1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.